Epizyme, a six-year-old, Cambridge, Mass.-based biopharmaceutical company that’s focused on researching treatments for tumors and blood cancers, has filed an S-1 with the SEC, in an offering whose underwriters include Citigroup, Cowen and Company, Leerink Swann, JMP Securities, and Wedbush PacGrow Life Sciences.
Epizyme has raised more than $50 million over the years, including from Bay City Capital, Amgen Ventures, Astellas Venture Management,MPM Capital, Kleiner Perkins Caufield & Byers, New Enterprise Associates, and GlaxoSmithKline.
The filing is here.
The post Epizyme Files for an IPO appeared first on peHUB.